相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Time to full publication of studies of anti-cancer medicines for breast cancer and the potential for publication bias: a short systematic review
A Takeda et al.
HEALTH TECHNOLOGY ASSESSMENT (2014)
Publication Bias and the Efficacy of Antidepressants
Sanjay J. Mathew et al.
AMERICAN JOURNAL OF PSYCHIATRY (2009)
Reporting Basic Results in ClinicalTrials.gov
Tony Tse et al.
CHEST (2009)
Update on Registration of Clinical Trials in ClinicalTrials.gov
Tony Tse et al.
CHEST (2009)
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
Philip D. Home et al.
LANCET (2009)
Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial
Peter Kenemans et al.
LANCET ONCOLOGY (2009)
Progress and Deficiencies in the Registration of Clinical Trials
Alastair J. J. Wood
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Outcome Reporting in Industry-Sponsored Trials of Gabapentin for Off-Label Use.
S. Swaroop Vedula et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The Neurontin legacy - Marketing through Misinformation and Manipulation
C. Seth Landefeld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Publication bias in clinical trials due to statistical significance or direction of trial results
Sally Hopewell et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2009)
Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis
Tom Jefferson et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
The ADVANTAGE seeding trial: A review of internal documents
Kevin P. Hill et al.
ANNALS OF INTERNAL MEDICINE (2008)
Negative pressure wound therapy: Potential publication bias caused by lack of access to unpublished study results data
Frank Peinemann et al.
BMC MEDICAL RESEARCH METHODOLOGY (2008)
Pharmaceutical company funding and its consequences: A qualitative systematic review
Sergio Sismondo
CONTEMPORARY CLINICAL TRIALS (2008)
International Dialogue on the Public Reporting Of Clinical Trial Outcome and Results – PROCTOR Meeting
Karmela Krleža-Jerić
CROATIAN MEDICAL JOURNAL (2008)
The Rosigliazone Meta-Analysis: Lessons for the future
J. J. Shuster et al.
DIABETES CARE (2008)
Critical lessons from the ENHANCE trial
Philip Greenland et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Controversies surround heart drug study questions about Vytorin and trial sponsors' conduct
Mike Mitka
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Guest authorship and ghostwriting in publications related to rofecoxib - A case study of industry documents from rofecoxib litigation
Joseph S. Ross et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment - A case study based on documents from rofecoxib litigation
Bruce M. Psaty et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Impugning the integrity of medical science - The adverse effects of industry influence
Catherine D. DeAngelis et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Publication bias in orthopedic research:: An analysis of scientific factors associated with publication in the journal of bone and joint surgery (American volume)
Kanu Okike et al.
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME (2008)
Clinical research projects at a German medical faculty:: follow-up from ethical approval to publication and citation by others
A. Bluemle et al.
JOURNAL OF MEDICAL ETHICS (2008)
Selective reporting in clinical trials:: analysis of trial protocols accepted by The Lancet
Sanaa Al-Marzouki et al.
LANCET (2008)
Simvastatin with or without ezetimibe in familial hypercholesterolemia
John J. P. Kastelein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Selective publication of antidepressant trials and its influence on apparent efficacy
Erick H. Turner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Commentary: Practicing on the Tip of an Information Iceberg? Evidence of Underpublication of Registered Clinical Trials in Oncology
Scott Ramsey et al.
ONCOLOGIST (2008)
Commentary: Publishing Cancer Clinical Trial Results: A Scientific and Ethical Imperative
James H. Doroshow
ONCOLOGIST (2008)
Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias
Kerry Dwan et al.
PLOS ONE (2008)
Closing a Loophole in the FDA Amendments Act
E. H. Turner et al.
SCIENCE (2008)
An untold story?
Jeanne Lenzer et al.
BRITISH MEDICAL JOURNAL (2008)
Publication of Clinical Trials Supporting Successful New Drug Applications: A Literature Analysis
Kirby Lee et al.
PLOS MEDICINE (2008)
Reporting Bias in Drug Trials Submitted to the Food and Drug Administration: Review of Publication and Presentation
Kristin Rising et al.
PLOS MEDICINE (2008)
Initial severity and antidepressant benefits: A meta-analysis of data submitted to the food and drug administration
Irving Kirsch et al.
PLOS MEDICINE (2008)
Almost all articles on cancer prognostic markers report statistically significant results
Panayiotis A. Kyzas et al.
EUROPEAN JOURNAL OF CANCER (2007)
Long-term risk of cardiovascular events with rosiglitazone - A meta-analysis
Sonal Singh et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Rosiglitazone evaluated for cardiovascular outcomes - An interim analysis
Philip D. Home et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
Steven E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Association between pharmaceutical involvement and outcomes in breast cancer clinical trials
Jeffrey Peppercorn et al.
CANCER (2007)
Confidentiality laws and secrecy in medical research: Improving public access to data on drug safety
Aaron S. Kesselheim et al.
HEALTH AFFAIRS (2007)
What have we learnt from Vioxx?
Harlan Krumholz et al.
BMJ-BRITISH MEDICAL JOURNAL (2007)
Characteristics and impact of drug detailing for gabapentin
Michael A. Steinman et al.
PLOS MEDICINE (2007)
Full publication of results initially presented in abstracts
R. W. Scherer et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2007)
Grey literature in meta-analyses of randomized trials of health care interventions
S. Hopewell et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2007)
Time to publication for results of clinical trials (Review)
S. Hopewell et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2007)
Relationship between drug company funding and outcomes of clinical psychiatric research
Robert E. Kelly et al.
PSYCHOLOGICAL MEDICINE (2006)
Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review
Anders W. Jorgensen et al.
BMJ-BRITISH MEDICAL JOURNAL (2006)
Peer-reviewed publication of clinical trials completed for pediatric exclusivity
Daniel K. Benjamin et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Narrative review: The promotion of gabapentin: An analysis of internal industry documents
Michael A. Steinman et al.
ANNALS OF INTERNAL MEDICINE (2006)
Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005
PM Ridker et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Constraints on publication rights in industry-initiated clinical trials
PC Gotzsche et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery
K Karkouti et al.
TRANSFUSION (2006)
Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: An exploratory analysis of head-to-head comparison studies of second-generation antipsychotics
S Heres et al.
AMERICAN JOURNAL OF PSYCHIATRY (2006)
The risk associated with aprotinin in cardiac surgery
DT Mangano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Under-reporting of adverse drug reactions - A systematic review
Lorna Hazell et al.
DRUG SAFETY (2006)
Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry
RH Perlis et al.
AMERICAN JOURNAL OF PSYCHIATRY (2005)
Lessons from the failure and recall of an implantable cardioverter-defibrillator
RG Hauser et al.
CIRCULATION (2005)
Selective reporting biases in cancer prognostic factor studies
PA Kyzas et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Fate of biomedical research protocols and publication bias in France: retrospective cohort study
E Decullier et al.
BMJ-BRITISH MEDICAL JOURNAL (2005)
Extent and impact of industry sponsorship conflicts of interest in dermatology research
CS Perlis et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2005)
Principles for international registration of protocol information and results from human trials of health related interventions: Ottawa statement (part 1)
K Krleza-Jeric et al.
BMJ-BRITISH MEDICAL JOURNAL (2005)
Short-term risk of death after treatment with nesiritide for decompensated heart failure - A pooled analysis of randomized controlled trials
JD Sackner-Bernstein et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors
AW Chan et al.
BMJ-BRITISH MEDICAL JOURNAL (2005)
Ambient particulate matter and health effects - Publication bias in studies of short-term associations
HR Anderson et al.
EPIDEMIOLOGY (2005)
Reporting of vaccine safety data in publications: systematic review
J Bonhoeffer et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2005)
Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data
CJ Whittington et al.
LANCET (2004)
Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research
AW Chan et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2004)
Prevalence and Outcomes of Pharmaceutical Industry-Sponsored Clinical Trials Involving Clozapine, Risperidone, or Olanzapine
Ric M. Procyshyn et al.
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE (2004)
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis
P Juni et al.
LANCET (2004)
Potential for conflict of interest in the evaluation of suspected adverse drug reactions - Use of cerivastatin and risk of rhabdomyolysis
BM Psaty et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia
JH Montgomery et al.
CONTROLLED CLINICAL TRIALS (2004)
SSRI treatment for under-18s - Response
EJ Garland
CANADIAN MEDICAL ASSOCIATION JOURNAL (2004)
SSRI treatment for under-18s - Response
A Herxheimer et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2004)
Empirical evidence for selective reporting of outcomes in randomized trials -: Comparison of Protocols to published articles
AW Chan et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Quantitative analysis of sponsorship bias in economic studies of antidepressants
CB Baker et al.
BRITISH JOURNAL OF PSYCHIATRY (2003)
Industry-sponsored economic studies in oncology vs studies sponsored by nonprofit organisations
M Hartmann et al.
BRITISH JOURNAL OF CANCER (2003)
Association of funding and conclusions in randomized drug trials - A reflection of treatment effect or adverse events?
B Als-Nielsen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Clozapine v. conventional antipsychotic drugs for treatment-resistant schizophrenia: a re-examination
J Moncrieff
BRITISH JOURNAL OF PSYCHIATRY (2003)
Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations
L Kaiser et al.
ARCHIVES OF INTERNAL MEDICINE (2003)
Registering clinical trials
K Dickersin et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Factors associated with failure to publish large randomized trials presented at an oncology meeting
MK Krzyzanowska et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Pharmaceutical industry sponsorship and research outcome and quality: systematic review
J Lexchin et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
Evidence b(i)ased medicine-selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications
H Melander et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
Role of a research ethics committee in follow-up and publication of results
J Pich et al.
LANCET (2003)
Scope and impact of financial conflicts of interest in biomedical research - A systematic review
JE Bekelman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
How useful are unpublished data from the Food and Drug Administration in meta-analysis?
CH MacLean et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2003)
COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease
WA Ray et al.
LANCET (2002)
Alosetron: a case study in regulatory capture, or a victory for patients' rights?
R Moynihan
BRITISH MEDICAL JOURNAL (2002)
Survey of public information about ongoing clinical trials funded by industry: evaluation of completeness and accessibility
E Manheimer et al.
BRITISH MEDICAL JOURNAL (2002)
Association between competing interests and authors' conclusions: epidemiological study of ramdomised clinical trials published in the BMJ
LL Kjaergard et al.
BMJ-BRITISH MEDICAL JOURNAL (2002)
Publication bias in editorial decision making
CM Olson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Citation bias of hepato-biliary randomized clinical trials
LL Kjaergard et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2002)
Data withholding in academic genetics - Evidence from a national survey
EG Campbell et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Risk of cardiovascular events associated with selective COX-2 inhibitors
D Mukherjee et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Completeness of safety reporting in randomized trials - An evaluation of 7 medical areas
JPA Ioannidis et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Alosetron for irritable bowel syndrome
E Barbehenn et al.
LANCET (2000)
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.
C Bombardier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Does the inclusion of grey literature influence estimates of intervention effectiveness reported in meta-analyses?
L McAuley et al.
LANCET (2000)
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis - The CLASS study: A randomized controlled trial
FE Silverstein et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial
M Camilleri et al.
LANCET (2000)
分享论文
